Narrative review highlights complement system activation in idiopathic pulmonary fibrosis, suggesting targeted complement inhibition as a viable therapeutic strategy.
Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease, and its pathogenesis remains unclear. In recent years, studies have shown that complement system activation plays an important role in the process of IPF. The inhibition of complement system activation provides a new approach for IPF treatment strategies. This article reviews the recent advances of complement system activation in the molecular mechanisms in the progress of IPF, and the potential therapeutic target in drug development, providing new perspectives for the prevention and treatment of IPF.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: